Skip to content
Screener

Ionis Pharmaceuticals IONS Payments to Acquire Property, Plant, and Equipment

Payments to Acquire Property, Plant, and Equipment at other companies

Pfizer logo
PfizerPFE
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Revenue$267.9M-40.7%
Gross profit$265.2M-40.8%
Operating income-$102.3M-173%
Net income-$114.6M-193%
EPS (diluted)-$0.69-199%

Balance sheet

See full
Cash & equivalents$350.1M+17.7%
Total debt$262.5M-67.0%
Total equity$439.7M-30.4%
Total assets$3.0B+0.3%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$16.1M+30.7%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$9.4B+44.4%
Enterprise value$9.31B+32.9%
P/S10.8×+3.9×

Profitability

See full
Gross margin98.2%-0.7pp
Operating margin-68%-234pp
Net margin-64.7%-299pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-105.5%+336pp
Debt / equity0.6×-0.7×
Current ratio7.9×+5.0×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000874015-26-000251
Line itemSix Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Investing activities:
Purchases of short-term investments(513,005)(802,657)
Proceeds from sale of short-term investments1,114,805880,545
Purchases of property, plant and equipment(37,843)(24,882)
Acquisition of licenses and other assets, net(3,640)(2,615)
Net cash provided by investing activities560,31750,391
Financing activities:
Proceeds from issuance of common stock through equity plans, net77,5603,528

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Ionis Pharmaceuticals's payments to acquire property, plant, and equipment?
Ionis Pharmaceuticals (IONS) reported payments to acquire property, plant, and equipment of $16.08M in Q2 2026.
How has Ionis Pharmaceuticals's payments to acquire property, plant, and equipment changed year-over-year?
Ionis Pharmaceuticals's payments to acquire property, plant, and equipment increased by 30.7% year-over-year, from $12.31M to $16.08M.
What is the long-term trend for Ionis Pharmaceuticals's payments to acquire property, plant, and equipment?
Over 4 years (2021 to 2025), Ionis Pharmaceuticals's payments to acquire property, plant, and equipment has grown at a 44.0% compound annual growth rate (CAGR), from $11.96M to $51.44M.
What does payments to acquire property, plant, and equipment mean?
Measures the cash outflows for capital expenditures (CapEx) related to the acquisition or construction of long-term physical assets. This reflects the company's investment in infrastructure, facilities, and equipment necessary for long-term growth.

Ask your AI about Ionis Pharmaceuticals's payments to acquire property, plant, and equipment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude